Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

BioNexus Gene Lab (BGLC) Tax Provisions (2018 - 2024)

BioNexus Gene Lab's Tax Provisions history spans 7 years, with the latest figure at -$80701.0 for Q4 2024.

  • Quarterly results put Tax Provisions at -$80701.0 for Q4 2024, up 17.6% from a year ago — trailing twelve months through Sep 2025 was -$80701.0 (down 32.57% YoY), and the annual figure for FY2024 was -$3494.0, up 83.77%.
  • Tax Provisions for Q4 2024 was -$80701.0 at BioNexus Gene Lab, down from $1555.0 in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $171488.0 in Q4 2020 to a low of -$97944.0 in Q4 2023.
  • The 5-year median for Tax Provisions is $10114.0 (2022), against an average of $22112.9.
  • The sharpest move saw Tax Provisions skyrocketed 22134.09% in 2021, then plummeted 482.3% in 2023.
  • Year by year, Tax Provisions stood at $171488.0 in 2020, then crashed by 52.71% to $81098.0 in 2021, then tumbled by 68.41% to $25620.0 in 2022, then plummeted by 482.3% to -$97944.0 in 2023, then grew by 17.6% to -$80701.0 in 2024.
  • According to Business Quant data, Tax Provisions over the past three periods came in at -$80701.0, $1555.0, and $55584.0 for Q4 2024, Q3 2024, and Q2 2024 respectively.